{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:39:10Z","timestamp":1787611150646,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH","award":["K99\/R00AI148604"],"award-info":[{"award-number":["K99\/R00AI148604"]}]},{"name":"Bay Area Lyme Foundation Emerging Leader Award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report Babesia microti genomic sequences with multiple mutations in the atovaquone-target region of cytochrome b, including a newly identified Y272S mutation, plus 1 mutation of undetermined significance in the azithromycin-associated ribosomal protein L4. The parasite was sequenced from an immunocompromised patient on prophylactic atovaquone for Pneumocystis pneumonia before diagnosis of babesiosis.<\/jats:p>","DOI":"10.1093\/ofid\/ofad097","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T15:08:26Z","timestamp":1677164906000},"source":"Crossref","is-referenced-by-count":17,"title":["<i>Babesia microti<\/i>\n                    Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-0507","authenticated-orcid":false,"given":"Nolan R","family":"Holbrook","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Infectious Diseases Division, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H","family":"Klontz","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C","family":"Adams","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R","family":"Schnittman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas C","family":"Issa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila A","family":"Bond","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Branda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E","family":"Lemieux","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.idc.2022.02.009","article-title":"Human babesiosis","volume":"36","author":"Waked","year":"2022","journal-title":"Infect Dis Clin North Am"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1093\/cid\/ciaa1216","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis","volume":"72","author":"Krause","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/649859","article-title":"Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection","volume":"50","author":"Wormser","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4269\/ajtmh.17-0146","article-title":"Risk factors for severe infection, hospitalization, and prolonged antimicrobial therapy in patients with babesiosis","volume":"97","author":"Mareedu","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"16079","DOI":"10.1038\/nmicrobiol.2016.79","article-title":"A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse","volume":"1","author":"Lemieux","year":"2016","journal-title":"Nat Microbiol"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/cid\/ciac473","article-title":"Broad antimicrobial resistance in a case of relapsing babesiosis successfully treated with tafenoquine","volume":"76","author":"Rogers","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix477","article-title":"Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia","volume":"65","author":"Simon","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01460","article-title":"Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone","volume":"27","author":"Marcos","year":"2022","journal-title":"IDCases"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jiab321","article-title":"Cytochrome b drug resistance mutation decreases babesia fitness in the tick stages but not the mammalian erythrocytic cycle","volume":"225","author":"Chiu","year":"2022","journal-title":"J Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/infdis\/jiaa195","article-title":"Clofazimine, a promising drug for the treatment of Babesia microti infection in severely immunocompromised hosts","volume":"222","author":"Tuvshintulga","year":"2020","journal-title":"J Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0006-2952(92)90213-3","article-title":"Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4\u2032-chlorophenyl) cyclohexyli-3-hydroxy-1,4-naphthoquinone (566c80)","volume":"43:","author":"Fry","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2958.1999.01515.x","article-title":"Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites","volume":"33","author":"Srivastava","year":"1999","journal-title":"Mol Microbiol"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1038\/ncomms5029","article-title":"Structural analysis of atovaquone-inhibited cytochrome bc 1 complex reveals the molecular basis of antimalarial drug action","volume":"5","author":"Birth","year":"2014","journal-title":"Nat Commun"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/AAC.44.8.2100-2108.2000","article-title":"Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site","volume":"44","author":"Korsinczky","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1074\/jbc.M111.324319","article-title":"Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression","volume":"287","author":"Fisher","year":"2012","journal-title":"J Biol Chem"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab323","article-title":"Relapsed Babesia microti infection following allogeneic hematopoietic cell transplantation in a patient with B-cell acute lymphoblastic leukemia: case report and review of the literature","volume":"8","author":"Rosenblatt","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1074\/jbc.M608615200","article-title":"In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin","volume":"282","author":"Sidhu","year":"2007","journal-title":"J Biol Chem"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.transci.2019.07.010","article-title":"Repeat exchange transfusion for treatment of severe babesiosis","volume":"58","author":"Radcliffe","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"2023032309172039100_","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.cell.2015.06.007","article-title":"Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone","volume":"161","author":"Park","year":"2015","journal-title":"Cell"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad097\/49319563\/ofad097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/3\/ofad097\/49601403\/ofad097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/3\/ofad097\/49601403\/ofad097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T06:15:48Z","timestamp":1679811348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad097\/7055919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad097","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.16.22283586","asserted-by":"object"}]},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,2,23]]},"article-number":"ofad097"}}